$0.18
-0.00 (-2.22%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where NWBO is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional · 1 expanded access
Held by 0 tracked-famous managers · FINRA short interest 10.8 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain CancerNCT00045968The primary objective of this study is to compare overall survival (OS) between patients randomized to DCVax-L and control patients from comparable, contemporaneous trials who received standard of care therapy only, in newly diagnosed glioblastoma.Randomized · Quadruple-masked · Treatment | Phase 3 | Unknown status | Drug: Dendritic cell immunotherapy | Glioblastoma Multiforme, Glioblastoma, GBM, Grade IV Astrocytoma, Glioma, Brain Cancer, Brain Tumor | 348 | Nov 2022 | 2022-05-18 |
| Dendritic Cell Therapy for Brain Metastases From Breast- or Lung CancerNCT03638765Safety is assessed graded according to NCI CTC. The overall incidence of adverse events is calculated.Open-label · Treatment | Phase 1 | Unknown status | Biological: DCVax-Direct | Brain Metastases, Lung Cancer Metastatic, Breast Cancer Metastatic | 24 | Dec 2019 | 2018-08-20 |
| Safety and Efficacy Study of DCVax-Direct in Solid TumorsNCT01882946Number of patients with adverse eventsOpen-label · Treatment | Phase 1/2 | Unknown status | Biological: DCVax-Direct | Locally Advanced Tumor, Metastatic Solid Tissue Tumors, Liver Cancer, Colorectal Cancer, Pancreatic Cancer, Melanoma | 60 | Dec 2016 | 2015-10-07 |
| Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.NCT00043212Randomized · Double-masked · Treatment | Phase 3 | Withdrawnsponsor's stated reason: Redirection of company goals | Drug: Dendritic cell immunotherapy | Prostate Cancer | 0 | — | 2013-05-01 |
| Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221NCT02146066expanded access | — | Available | Biological: DCVax-L | GBM, Glioblastoma Multiforme | — | — | 2016-02-26 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19